Published in:
01-08-2009 | Original Article
Long-term outcome of idiopathic steroid-resistant nephrotic syndrome: a multicenter study
Authors:
Djalila Mekahli, Aurelia Liutkus, Bruno Ranchin, Anchalee Yu, Lucie Bessenay, Eric Girardin, Rita Van Damme-Lombaerts, Jean-Bernard Palcoux, François Cachat, Marie-Pierre Lavocat, Guylhène Bourdat-Michel, François Nobili, Pierre Cochat
Published in:
Pediatric Nephrology
|
Issue 8/2009
Login to get access
Abstract
Long-term outcome of idiopathic steroid-resistant nephrotic syndrome was retrospectively studied in 78 children in eight centers for the past 20 years. Median age at onset was 4.4 years (1.1–15.0 years) and the gender ratio was 1.4. Median follow-up period was 7.7 years (1.0–19.7 years). The disease in 45 patients (58%) was initially not steroid-responsive and in 33 (42%) it was later non-responsive. The main therapeutic strategies included administration of ciclosporine (CsA) alone (n = 29; 37%) and CsA + mycophenolate mofetil (n = 18; 23%). Actuarial patient survival rate after 15 years was 97%. Renal survival rate after 5 years, 10 years and 15 years was 75%, 58% and 53%, respectively. An age at onset of nephrotic syndrome (NS) > 10 years was the only independent predictor of end-stage renal disease (ESRD) in a multivariate analysis using a Cox regression model (P < 0.001). Twenty patients (26%) received transplants; ten showed recurrence of the NS: seven within 2 days, one within 2 weeks, and two within 3–5 months. Seven patients lost their grafts, four from recurrence. Owing to better management, kidney survival in idiopathic steroid-resistant nephrotic syndrome (SRNS) has improved during the past 20 years. Further prospective controlled trials will delineate the potential benefit of new immunosuppressive treatment.